adaptor related protein complex 3 subunit sigma 2Genealiases: AP3S3 · sigma3b
Q-omics provides the consensus-scored AP3S2 profile across patient tissues and cancer cell-line models. AP3S2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AP3S2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, AP3S2 RNA expression shows 20,780 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where AP3S2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AP3S2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AP3S2 survival associations across molecular data types. AP3S2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AP3S2 RNA expression–survival associations across cancer types. High AP3S2 expression shows unfavorable associations in UVM, ACC and DLBC, but favorable associations in KIRC, KIRP and SARC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AP3S2 RNA expression.
This table summarizes AP3S2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for AP3S2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AP3S2 shows lower tumor expression in COAD, THCA, KIRC, KICH and KIRP and higher tumor expression in LIHC. The COAD box plot shows higher AP3S2 RNA expression in normal versus tumor tissue (log2 FC = −1.061, t-test p < 0.001).
This table shows molecular features associated with AP3S2 in patient tissues and cancer cell lines. In patient samples, AP3S2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, AP3S2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
